ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Haematology · Lancet Haematol · 2026-06-12

In a phase 2 trial of 88 older adults with newly diagnosed DLBCL unfit for anthracyclines, complete response was 63.6% with epcoritamab alone vs 45.5% with epcoritamab plus lenalidomide; serious adverse events 64% vs 81%. Monotherapy went forward to expansion.

RCTn = 111
Vitolo et al. Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
Oncology · Lancet · 2026-05-30

In 899 adults with untreated high-risk DLBCL or HGBL, adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival vs R-CHOP plus placebo (HR 0·75; 2-year 71·1% vs 62·9%), but grade ≥3 (87% vs 76%) and fatal adverse events (6% vs 4%) were higher.

RCTn = 899
Lenz et al. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial
Haematology · Haematologica · 2026-04-16

Phase 2 randomised non-comparative trial in 92 patients with relapsed/refractory follicular lymphoma, stopped early for slow accrual: CR at end of induction 11.4% with lenalidomide-rituximab vs 15.2% with added bendamustine; severe toxicity 6.8% vs 13.0%.

RCTn = 92
Kersten et al. Lenalidomide-rituximab or lenalidomide-rituximabbendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.